2022年12月5日

領投方ARCH Venture Partners與Illumina Ventures、Johnson & Johnson Innovation - JJDC, Inc.、Vertex Ventures HC、Medical Excellence Capital等在全球生物技術和製藥領域進行投資。資金將用於平台優化、臨床前開發、早期製造和初步人體概念驗證。SonoThera的技術平台和治療方法旨在克服基因治療中最重要的交付挑戰。SonoThera的平台使用微泡介導的生物物理過程，無創地輸送不同格式和大小的核酸有效載荷，選擇性地針對體內的廣泛器官。加利福尼亞州舊金山南部——(美國商業資訊)——生物技術公司SonoThera™今天宣布完成600.75億美元的a輪融資，該公司致力於通過基因療法治療人類疾病的根本原因。此次融資將支持SonoThera的超聲引導、非病毒基因治療平台和治療方法的持續發展，旨在為患者提供基因藥物。領投方ARCH Venture Partners、Illumina Ventures、Johnson & Johnson Innovation - JJDC, Inc.、Vertex Ventures HC和Medical Excellence Capital也加入了該項目。參與這輪融資的還有禮來公司、Alexandria Venture Investments、Lifespan Investments、Formic Ventures、Foothill Ventures和Wilson Sonsini。SonoThera聯合創始人兼首席執行官Kenneth Greenberg博士表示:“我們很高興能達到這一重要的裏程碑，這推動了我們的平台技術開發和SonoThera的發展。“投資者的大力支持進一步促進了我們的臨床前開發和早期製造活動，與此同時，我們戰略性地建立了我們的團隊。 Each step brings us closer to one day making our nonviral gene therapies a reality for patients and providers.” SonoThera’s ultrasound-guided platform uses sonoporation, a microbubble-mediated biophysical process to non-invasively deliver genetic payloads of diverse formats and sizes, selectively targeting a wide range of organs within the body. Unlike traditional gene therapies, the technology does not require viral vectors which can be immunogenic and lead to both safety and efficacy challenges. “We believe in the innovation SonoThera is developing to provide a new generation of genetic medicines and are pleased to contribute to its success,” said Steven Gillis, PhD, of ARCH Venture Partners. “The concept of a targeted, non-invasive, nonviral therapy which could deliver a variety of payloads would significantly change the genetic treatment paradigm for patients, potentially across a variety of disease states.” About SonoThera™ Founded by Drs. Kenneth Greenberg, Michael Davidson, and Steve Feinstein, SonoThera, Inc. is a biotechnology company dedicated to treating the root cause of human disease through genetic therapy. SonoThera is developing an ultrasound-guided, nonviral gene therapy platform and treatments designed to provide patients with the next generation of safe and effective genetic medicines. The platform utilizes sonoporation, a microbubble-mediated biophysical process to non-invasively deliver genetic payloads selectively targeting a wide range of organs within the body. SonoThera is headquartered in South San Francisco, California. Visit www.sonothera.com to learn more. Contacts